Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Azenta Inc. (AZTA) Insider Trading Activity
Healthcare • Medical Instruments & Supplies • 3,300 employees
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Total Value
$9,358,595.51
Total Shares
220,458
Average Trade Value
$283,593.80
Most Active Insider
Marotta John
Total Activity: $4,024,014
Largest Single Transaction
$3,471,149
by Marotta John on Nov 15, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Evp, CFO and Treasurer
|
Feb 11, 2025 | 2,200 | $101,200 | 37,513 (+5.9%) | Grant | |
Feb 7, 2025 | 4,040 | $211,373 | 5,035 (+80.2%) | Grant | ||
Feb 7, 2025 | 4,040 | $211,373 | 33,627 (+12.0%) | Grant | ||
Feb 7, 2025 | 4,040 | $211,373 | 16,858 (+24.0%) | Grant | ||
Feb 7, 2025 | 4,040 | $211,373 | 4,040 (+100.0%) | Grant | ||
Director
|
Feb 7, 2025 | 4,040 | $52,320 | 5,035 (+80.2%) | Grant | |
Feb 7, 2025 | 4,040 | $211,373 | 10,109 (+40.0%) | Grant | ||
Feb 7, 2025 | 5,168 | $270,390 | 14,560 (+35.5%) | Grant | ||
Vp, Chief Accounting Officer
|
Feb 3, 2025 | 317 | $16,791 | 9,603 (-3.3%) | Sale | |
SVP and General Manager, Genom
|
Jan 31, 2025 | 417 | $19,132 | 27,916 (+1.5%) | Purchase | |
Evp, CFO and Treasurer
|
Dec 5, 2024 | 23,045 | $1,037,025 | 29,545 (+78.0%) | Grant | |
Evp, CFO and Treasurer
|
Dec 5, 2024 | 5,768 | $259,560 | 35,313 (+16.3%) | Grant | |
SVP Gm, Sms
|
Dec 4, 2024 | 140 | $6,531 | 23,974 (-0.6%) | Sale to Issuer | |
Vp, Chief Accounting Officer
|
Nov 19, 2024 | 163 | $6,531 | 9,920 (-1.6%) | Sale | |
President and CEO
|
Nov 19, 2024 | 1,250 | $50,838 | 100,861 (+1.2%) | Purchase | |
Nov 19, 2024 | 4,940 | $201,404 | 7,405 (+66.7%) | Purchase | ||
SVP Gm, Sms
|
Nov 19, 2024 | 348 | $13,944 | 24,114 (-1.4%) | Sale | |
Svp, General Counsel, Secy.
|
Nov 19, 2024 | 1,139 | $45,640 | 112,564 (-1.0%) | Sale | |
SVP and Chro
|
Nov 19, 2024 | 548 | $21,958 | 19,373 (-2.8%) | Sale | |
Evp, Chief Financial Officer
|
Nov 19, 2024 | 712 | $28,530 | 23,892 (-3.0%) | Sale | |
SVP and General Manager, Genom
|
Nov 19, 2024 | 491 | $19,674 | 27,499 (-1.8%) | Sale | |
President and CEO
|
Nov 18, 2024 | 12,716 | $502,028 | 99,611 (+12.8%) | Purchase | |
Nov 18, 2024 | 12,500 | $495,000 | 14,755 (+84.7%) | Purchase | ||
Nov 18, 2024 | 1,000 | $39,500 | 3,465 (+28.9%) | Purchase | ||
Vp, Chief Accounting Officer
|
Nov 15, 2024 | 6,921 | $287,291 | 10,083 (+68.6%) | Grant | |
President and CEO
|
Nov 15, 2024 | 83,622 | $3,471,149 | 86,895 (+96.2%) | Grant | |
Svp, General Counsel, Secy.
|
Nov 15, 2024 | 13,841 | $574,540 | 113,703 (+12.2%) | Grant | |
SVP Gm, Sms
|
Nov 15, 2024 | 8,651 | $359,103 | 24,462 (+35.4%) | Grant | |
SVP and Chro
|
Nov 15, 2024 | 10,381 | $430,915 | 19,921 (+52.1%) | Grant | |
SVP and General Manager, Genom
|
Nov 15, 2024 | 8,651 | $359,103 | 27,990 (+30.9%) | Grant | |
Nov 6, 2024 | 995 | $46,287 | 995 (-100.0%) | Sale to Issuer | ||
Nov 6, 2024 | 995 | $46,287 | 2,255 (-44.1%) | Sale to Issuer | ||
Director
|
Nov 6, 2024 | 995 | $43,410 | 995 (+100.0%) | Grant |